FDA Issues Correction for Tandem Diabetes Care t:slim X2 Insulin Pumps Over Speaker Wiring Defect

September 15, 2025 — Washington, D.C.

The U.S. Food and Drug Administration (FDA) has announced a Class II device correction for the t:slim X2 insulin pump, a widely used device manufactured by Tandem Diabetes Care. The action follows reports of improperly installed speaker wires in a subset of pumps, which may cause alarms to fail or insulin delivery to be disrupted. While the devices are not being removed from the market, Tandem and the FDA are emphasizing urgent corrective actions to prevent potential patient harm.

The t:slim X2 insulin pump is a touchscreen-enabled device designed for continuous subcutaneous insulin infusion. It is often paired with Dexcom continuous glucose monitors (CGMs) as part of an automated insulin delivery ecosystem.

According to the FDA’s correction notice, certain pumps were manufactured with defective speaker wiring that can result in:

• Audio alarm failure, leaving patients unaware of pump malfunctions or low insulin warnings

• Short circuits inside the pump, which could cause temporary loss of therapy

• Unintended therapy interruption, raising the risk of hyperglycemia or, in severe cases, diabetic ketoacidosis (DKA)

Unlike a Class I recall, where devices are pulled from clinical use, this action has been categorized as a Class II correction. That means Tandem is expected to provide technical updates, replacements, and support — without requiring all patients to immediately stop using the devices.

Why This Matters to the Surgical and Clinical Market

Insulin pumps are considered life-sustaining devices because of their central role in glucose management for type 1 diabetes and certain type 2 diabetes patients. Any disruption in therapy can trigger dangerous complications within hours.

The t:slim X2 is among the most widely prescribed insulin pumps in the United States. Its integration with CGMs has made it a preferred option for closed-loop therapy, where insulin delivery is automatically adjusted based on real-time glucose levels.

Failures in this device have several downstream consequences:

• Patient Safety Risks — Missed alarms or therapy interruptions increase the likelihood of hospitalizations for uncontrolled blood sugar or DKA.

• Clinical Burden — Endocrinologists, diabetes educators, and hospital diabetes care teams will need to intensify patient monitoring and reinforce backup insulin protocols.

• Operational Strain — Hospitals and outpatient clinics may see higher demand for emergency supplies (insulin pens, syringes) as patients prepare for the possibility of pump malfunction.

• Financial Impact — Device corrections often lead to warranty claims, replacement costs, and training overhead for providers and healthcare systems.

Individuals currently using affected t:slim X2 insulin pumps face the most immediate risks. These patients may miss critical alerts related to insulin delivery errors, reservoir depletion, or infusion set blockages. The FDA recommends that patients do not discontinue use abruptly but instead verify their device status with Tandem and ensure backup insulin delivery methods are available.

Endocrinologists, diabetes specialists, and certified diabetes educators will need to:

• Identify which of their patients are using the affected devices

• Reinforce education about recognizing silent failures

• Provide emergency insulin transition plans for patients in case of pump malfunction

Healthcare systems must prepare for potential increases in urgent admissions related to hyperglycemia and stockpile insulin pens and syringes for patients transitioning away from pumps, even temporarily. Pharmacies may also experience higher demand for short-acting insulin formulations as backup therapy.

Tandem Diabetes Care has issued a series of corrective steps in collaboration with the FDA:

1. Patient Notifications — Direct outreach is being conducted to inform users about the correction and the steps required to mitigate risk.

2. Software and Firmware Updates — Tandem is deploying updates to ensure that device safety is maintained even if the speaker malfunctions.

3. Technical Support and Replacement Options — Affected patients are being provided with troubleshooting assistance, and replacement devices will be offered where the risk of malfunction is high.

4. Guidance for Continued Use — Patients are being advised to continue using their pumps while following enhanced monitoring practices, unless specifically directed otherwise by their healthcare provider.

The FDA has emphasized that abrupt discontinuation of insulin pump therapy may itself be dangerous, underscoring the need for coordinated corrective action rather than widespread device withdrawal.

“Any disruption in insulin pump therapy is potentially dangerous. Patients must have clear communication from Tandem and their healthcare team, including backup plans for insulin delivery if their pump fails.”

— Dr. George Grunberger, Endocrinologist and Past President of the American Association of Clinical Endocrinologists

Industry experts note that the growing reliance on connected diabetes devices makes robust quality control and rapid recall response more critical than ever. As insulin pumps become more technologically sophisticated, hardware defects and software vulnerabilities alike carry significant clinical implications.

Strategic Implications for Hospitals and Procurement

This correction highlights a broader challenge for hospitals and ambulatory care providers:

• Vendor Accountability — Procurement teams are increasingly prioritizing manufacturers that provide robust recall support and rapid field corrections.

• Emergency Preparedness — Hospitals must develop protocols for device-dependent patients, ensuring backup therapies are always available.

• Supply Chain Risk — Even a correction, as opposed to a full recall, can cause temporary shortages of replacement devices or accessories, requiring proactive stock management.

The correction also underscores the need for data-driven monitoring systems that can detect early warning signs of device malfunction, whether hardware or software-based.

Patients: Confirm whether your device is affected by reviewing Tandem’s official correction notice and contact your healthcare provider for guidance. Always maintain a supply of backup insulin delivery tools.

Clinicians: Review your patient panels for t:slim X2 users, reinforce education on silent pump failures, and develop patient-specific emergency insulin plans.

Hospitals and Pharmacies: Stock additional insulin pens and syringes, prepare for potential therapy disruptions, and ensure diabetes care teams are aware of the FDA’s correction notice.